Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021
Longeveron Inc. (NASDAQ: LGVN) announced it will release its first quarter 2021 financial results on May 14, 2021, before US market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced it will release its first quarter 2021 financial results on May 14, 2021, before US market open. Management will host a conference call at 8:30 AM that day. The company focuses on cellular therapies for aging-related and life-threatening conditions, with its lead product, LOMECEL-B™, undergoing Phase 1 and 2 clinical trials for various serious conditions, including Aging Frailty and Alzheimer's disease. The aim is to advance therapies into pivotal Phase 3 trials for regulatory approval and commercialization.
Positive
- Lead product LOMECEL-B™ is in Phase 1 and 2 clinical trials for serious conditions.
- Focus on aging-related therapies may tap into growing demand in healthcare.
Negative
- None.
Details
News Market Reaction – LGVN
The recorded move for LGVN in the trading session of this news was -2.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first quarter 2021 financial results on Friday, May 14, 2021 before the open of US markets. Management will host a conference call on the same day at 8:30 AM.
To access the live conference, please dial 1-844-200-6205 from the United States or +44 208-0682-558 from other locations, and using entry code 460592. A webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at www.longeveron.com. A replay of the call will be available on the Longeveron website shortly after completion of the call.
About Longeveron
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.
Contact:
Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com
Source: Longeveron Inc
Source: LGVN
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.